South African tycoon Stephen Saad's Aspen opens regional headquarters in Saudi Arabia
Aspen’s investment comes amid a broader push to localize manufacturing, enhance drug supply chains, and develop regional talent.
Aspen Pharmacare
Stephen Saad’s Aspen stake drops $21 million in value
This mirrors wider investor caution amid challenges facing the global pharmaceutical sector and instability in emerging markets.
Stephen Saad raises Aspen stake by $5.6 million amid stock slump
Stephen Saad invests $5.6 million more in Aspen amid its biggest stock slump in two decades, signaling confidence in the company’s long-term outlook.
Stephen Saad loses $130 million as Aspen shares fall amid contract dispute
This follows a $148.7 million contract dispute tied to mRNA technology.
Stephen Saad’s Aspen faces $148.7 million contract dispute
Aspen shares dive 30% amid $148.7 million mRNA tech dispute, stoking investor fears over financial stability.
Gus Attridge gains over $18 million as Aspen shares rebound
This follows a strong recovery in Aspen's share price on the Johannesburg Stock Exchange (JSE).
Stephen Saad’s stake in Aspen slips below $450 million
South African pharma tycoon Stephen Saad’s stake in Aspen Pharmacare drops to $434.35 million, losing $62.85 million in 15 days.
South African tycoon Gus Attridge loses $15.73 Million as Aspen stake sinks
Attridge, co-founder and group chief advisor of Aspen Pharmacare, holds a 4.3-percent stake in the company.
Stephen Saad’s wealth takes a hit as Aspen Pharmacare stock plunges, erasing $41 million
This downturn follows a $44 million gain in January, which had lifted his stake to R10.26 billion ($550.1 million).
Stephen Saad leads Africa’s largest drugmaker to $1.2 billion in half-year revenue
The growth was fueled by the successful integration of acquired products in Latin America.
Africa’s largest asset manager buys additional stake worth $67 million in Stephen Saad’s Aspen Pharmacare
With this latest transaction, PIC’s stake in Aspen is now worth nearly a billion dollars—R15.2 billion ($824.24 million).
South African pharma tycoon Stephen Saad’s Aspen stake rises above $550 million
With the recent rise in Aspen's stock price, the value of his holdings has crossed $550 million, marking a recovery after a challenging 2024.
South African businessman Gus Attridge sees Aspen stake drop by $9.3 million
This corresponds to a 5.24 percent drop in Aspen’s stock price on the Johannesburg Stock Exchange (JSE) in 9 days.
Stephen Saad’s Aspen stake drops $99.7 million in 2024
This downturn is driven by a sustained decline in the market value of his holdings in Aspen Pharmacare, Africa's largest pharmaceutical company.
Gus Attridge's Aspen stake down $39 million so far in 2024
This corresponds to an 18.12 percent drop in Aspen’s stock price on the Johannesburg Stock Exchange (JSE) since the start of the year.
Gus Attridge’s stake in Africa’s largest pharma company drops by $16.5 million
South African pharma mogul Gus Attridge loses $16.5 million from stake in Africa’s largest pharmaceutical company.